CO6300940A2 - Derivados de espiro-indol para el tratamiento de enfermedades parasitarias - Google Patents

Derivados de espiro-indol para el tratamiento de enfermedades parasitarias

Info

Publication number
CO6300940A2
CO6300940A2 CO10148514A CO10148514A CO6300940A2 CO 6300940 A2 CO6300940 A2 CO 6300940A2 CO 10148514 A CO10148514 A CO 10148514A CO 10148514 A CO10148514 A CO 10148514A CO 6300940 A2 CO6300940 A2 CO 6300940A2
Authority
CO
Colombia
Prior art keywords
treatment
plasmodium
espiro
indol
derivatives
Prior art date
Application number
CO10148514A
Other languages
English (en)
Inventor
Shi Hua Ang
Philipp Krastel
Seh Leong
Liying Tan
Wei J Wong
Bryan Yeung
Bin Zou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40613087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300940(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6300940A2 publication Critical patent/CO6300940A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos orgánicos, los cuales tienen propiedades farmacéuticas interesantes. En particular, los compuestos son útiles en el tratamiento y/o la prevención de infecciones tales como aquéllas causadas por Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi y parásitos del género Leishmania, tales como, por ejemplo, Leisbmania donovani. La invención también se refiere a composiciones farmacéuticas que contienen los compuestos, así como a los procesos para su preparación.
CO10148514A 2008-04-29 2010-11-25 Derivados de espiro-indol para el tratamiento de enfermedades parasitarias CO6300940A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08155342 2008-04-29
EP09151117 2009-01-22

Publications (1)

Publication Number Publication Date
CO6300940A2 true CO6300940A2 (es) 2011-07-21

Family

ID=40613087

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10148514A CO6300940A2 (es) 2008-04-29 2010-11-25 Derivados de espiro-indol para el tratamiento de enfermedades parasitarias

Country Status (31)

Country Link
US (2) US8053442B2 (es)
EP (2) EP2285808B1 (es)
JP (2) JP5438098B2 (es)
KR (1) KR101390081B1 (es)
CN (1) CN102015711B (es)
AR (1) AR071222A1 (es)
AU (1) AU2009242279B2 (es)
BR (1) BRPI0911577B8 (es)
CA (1) CA2719365C (es)
CL (1) CL2009001007A1 (es)
CO (1) CO6300940A2 (es)
CY (1) CY1114874T1 (es)
DK (1) DK2285808T3 (es)
EA (1) EA019601B1 (es)
EC (2) ECSP10010646A (es)
ES (1) ES2447590T3 (es)
HK (1) HK1149935A1 (es)
HR (1) HRP20140151T1 (es)
IL (1) IL208357A (es)
JO (1) JO2904B1 (es)
MA (1) MA32316B1 (es)
MX (1) MX2010011868A (es)
MY (2) MY152021A (es)
NZ (1) NZ588217A (es)
PE (1) PE20091787A1 (es)
PL (1) PL2285808T3 (es)
PT (1) PT2285808E (es)
SI (1) SI2285808T1 (es)
TW (1) TWI442921B (es)
WO (1) WO2009132921A1 (es)
ZA (1) ZA201006752B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285808B1 (en) * 2008-04-29 2013-11-20 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases
CN102584835B (zh) * 2011-01-17 2014-08-27 苏州大学 一种含吲哚结构的螺杂环化合物及其制备方法
SG11201405990PA (en) 2012-03-23 2014-11-27 Codexis Inc Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
KR102057590B1 (ko) * 2012-03-23 2019-12-19 노파르티스 아게 스피로인돌론을 제조하기 위한 화학적 방법 및 그의 중간체
CN104185634B (zh) * 2012-03-23 2017-05-03 诺华股份有限公司 制备螺旋吲哚酮和其中间体的化学工艺
CN106232619B (zh) 2013-11-13 2022-09-09 科德克希思公司 工程化的亚胺还原酶和用于酮和胺化合物的还原胺化的方法
US10370648B2 (en) 2014-11-25 2019-08-06 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
KR102559719B1 (ko) 2014-12-18 2023-07-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
CR20170339A (es) * 2015-01-23 2018-01-22 Glaxosmithkline Ip Dev Ltd Derivados de pirazol[3,4-d] pirimidina y su uso para el tratamiento de leshmaniasis
WO2016147205A1 (en) * 2015-03-13 2016-09-22 Council Of Scientific & Industrial Research Novel substituted 3-spirophosphoryl pyrazole-2-oxindoles as anti-infectives and process for the synthesis thereof
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
JP2017024992A (ja) * 2015-07-15 2017-02-02 公益財団法人微生物化学研究会 化合物の製造方法
PE20211207A1 (es) 2018-06-21 2021-07-05 Hoffmann La Roche Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1- (3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso
CN110590795B (zh) * 2019-10-10 2021-01-22 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一类多并杂环螺羟吲哚类化合物的合成方法
US20230132973A1 (en) * 2020-03-17 2023-05-04 The University Of Buea DIHYDRO-SPIRO[INDOLINE-3:1'-iSOQUINOLIN]-2-ONES AS ANTIMALARIAL AGENTS
CN116273188B (zh) * 2023-03-01 2024-06-25 岭南师范学院 一种负载金属的多孔有机框架材料在催化Pictet-Spengler反应中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
WO2000004024A1 (en) * 1998-07-14 2000-01-27 Bayer Aktiengesellschaft Antiparasitic artemisinin derivatives (endoperoxides)
AU764820C (en) 1998-12-19 2004-11-18 Janssen Pharmaceutica N.V. Antihistaminic spiro compounds
US20050143371A1 (en) 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
BRPI0720004A2 (pt) 2006-12-07 2013-12-17 Hoffmann La Roche Derivados de espiro-piperidina como antagonista de receptor v1a
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN102015708B (zh) 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
EP2285808B1 (en) * 2008-04-29 2013-11-20 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases

Also Published As

Publication number Publication date
JP5438098B2 (ja) 2014-03-12
MX2010011868A (es) 2010-11-26
US8399453B2 (en) 2013-03-19
AU2009242279A1 (en) 2009-11-05
BRPI0911577B8 (pt) 2021-05-25
US20090275560A1 (en) 2009-11-05
CY1114874T1 (el) 2016-12-14
SI2285808T1 (sl) 2014-03-31
DK2285808T3 (da) 2014-02-03
EP2285808B1 (en) 2013-11-20
CA2719365C (en) 2017-03-07
IL208357A0 (en) 2010-12-30
ECSP17068127A (es) 2017-10-31
IL208357A (en) 2014-11-30
AU2009242279B2 (en) 2012-08-30
CN102015711A (zh) 2011-04-13
MY152021A (en) 2014-08-15
CA2719365A1 (en) 2009-11-05
BRPI0911577A2 (pt) 2016-01-05
ECSP10010646A (es) 2010-12-30
CL2009001007A1 (es) 2010-06-11
KR101390081B1 (ko) 2014-04-29
MY156601A (en) 2016-03-15
EA201001689A1 (ru) 2011-08-30
EP2285808A1 (en) 2011-02-23
KR20100135320A (ko) 2010-12-24
MA32316B1 (fr) 2011-05-02
HK1149935A1 (en) 2011-10-21
AR071222A1 (es) 2010-06-02
PE20091787A1 (es) 2009-12-14
PT2285808E (pt) 2014-02-24
BRPI0911577B1 (pt) 2021-02-23
ZA201006752B (en) 2011-05-25
HRP20140151T1 (hr) 2014-03-28
EP2722333A1 (en) 2014-04-23
JP2014065729A (ja) 2014-04-17
EA019601B1 (ru) 2014-04-30
TW200948357A (en) 2009-12-01
ES2447590T3 (es) 2014-03-12
TWI442921B (zh) 2014-07-01
US8053442B2 (en) 2011-11-08
NZ588217A (en) 2012-10-26
WO2009132921A1 (en) 2009-11-05
US20110275613A1 (en) 2011-11-10
JO2904B1 (en) 2015-09-15
BRPI0911577A8 (pt) 2018-03-06
JP2011518852A (ja) 2011-06-30
PL2285808T3 (pl) 2014-04-30
CN102015711B (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
ECSP17068127A (es) Derivados de espiro-indol para el tratamiento de enfermedades parasitarias
NI200700260A (es) Antagonistas de npy, preparación y usos.
CY1119684T1 (el) Αντι-ιικες ενωσεις
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
ECSP14017584A (es) Compuestos inhibidores de raf
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
BRPI0916456A2 (pt) composto e composição lipídicos e respectivos métodos de produção e usos (incluindo método de tratamento e de prevenção de doenças que utilizam os mesmos)
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
UY32848A (es) Compuestos heterocíclicos de oxima
CO6771450A2 (es) Ureas asimétricas y usos médicos de las mismas
CO6321288A2 (es) Sales de compuestos inhibidores de vih
IN2012DN01684A (es)
CU24011B1 (es) Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas
UY32016A (es) Compuesto de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
TN2010000458A1 (en) Spiro indole derivatives for the treatment of parasitic diseases
UY36469A (es) Nuevo compuesto de tiotriazol
UA106223C2 (en) Sulfamoyl-phenyl-ureido benzamidine-derivatives as antimalarial agents
TH106774A (th) อนุพันธ์สไปโร-อินโดลสำหรับการบำบัดโรคจากเชื้อปรสิตสาขาวิทยาการที่เกี่ยวข้องกับการประดิษฐ์
TH149183B (th) การใช้เฟอร์โรควินในการรักษาหรือป้องกันมาลาเรีย
CU20100147A7 (es) Pirrolo-pirimidinas y pirrolo-piridinas
CU20100011A7 (es) Compuestos orgánicos

Legal Events

Date Code Title Description
FG Application granted